CTOs on the Move

Karuna Therapeutics

www.karunatx.com

 
At Karuna, our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Through the cultivation of our deep expertise in neuroscience, and inventive thinking around drug discovery and development, we are advancing a pipeline of novel medicines with the goal of providing a meaningful difference in the lives of those affected by these conditions. Our culture is defined by our passion to serve those affected by mental illness. We are purpose-driven and intentional. We know impactful innovations don`t come easy, but are borne from passion and hard work. Together, we are working ...
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.karunatx.com
  • 99 High Street Floor 26
    Boston, MA USA 02110
  • Phone: 857.449.2244

Executives

Name Title Contact Details
Chris MacKenzie
 Head Of Information Technology Profile
Jason Siglasky
 Head Of Information Technology Profile

Similar Companies

Concept Medical

Concept Medical Inc. (CMI) is establishment of USA with the vision of `Inspiring Innovation`. CMI was founded in year 2008, having the mission of `converting concepts into reality` in the field of drug delivering medical devices industry.

Precision Health Media

New York-based Precision Health Media (formerly Good Health Media) delivers specific health condition audiences to pharma and consumer brands.

Anagenex

Discovering new medicines by combining ultra throughput biochemistry and machine learning.

THEON Therapeutics

THEON is a patient-focused drug discovery company developing small molecule correctors of RNA pathobiology.

Frontier Medicines

Frontier Medicines is a pre-clinical stage biopharmaceutical company developing breakthrough medicines that redefine the course of debilitating diseases. According to the American Cancer Society, 1,762,000 new cancer cases and 607,000 deaths from cancer are expected to occur in the US in 2019. Our focus is developing treatments against important cancer-causing proteins that the biopharma industry hasn`t found a way to treat (or “drug”) with pharmaceutical interventions. After decades of research, this has become one of the most critical challenges in addressing human disease and advancing oncology therapy --central to the research at Frontier Medicines. Frontier Medicines is using chemoproteomics – an innovative approach to chemically interrogate proteins in living systems – to discover and pharmacologically target new binding pockets (or “hotspots”) on proteins, making them accessible to small-molecule drug discovery and development. The company`s proprietary chemoproteomics platform also integrates advanced computational approaches and machine learning to further accelerate the path to drug discovery.